ACETO Announces Strategic Hires at Rising Pharmaceuticals
PORT WASHINGTON, N.Y., Sept. 6, 2013 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Rising Pharmaceuticals subsidiary has hired Paul Krauthauser as Senior Vice President, Sales and Marketing, and Sherri Leonard as Vice President, Portfolio Strategy.
Sal Guccione, Chief Executive Officer of ACETO, commented, "We are excited to be adding Paul and Sherri to ACETO and the Rising Pharmaceuticals team. They bring with them experience and knowledge which will enhance the Company's ability to capitalize on the significant opportunities that exist in the market for generic drugs.
In a short period of time as President and Chief Operating Officer of Rising Pharmaceuticals, Satish Srinivasan has done an excellent job bringing on highly skilled, experienced people. We look forward to the contributions that Paul and Sherri will bring to ACETO as we continue to focus on expanding our generic drug business."
Paul has 17 years of experience in the pharmaceutical industry, a majority of which has been focused on product marketing and sales. Most recently, Paul served as Director of National Accounts at Sandoz Inc., a division of Novartis Group and the second largest generic pharmaceuticals company globally. Prior to that, he worked in various roles at Apotex Corp. and Teva Pharmaceuticals. Paul received his B.S.
in Chemistry from De Sales University, and an MBA in Marketing from St.
Sherri has worked in the pharmaceutical industry for over 25 years with significant experience in portfolio strategy, project management, business development, research and development, and regulatory affairs.
She was last with Orchidpharma Inc., where she served as Vice President, Business Development and Portfolio Management. Previously, Sherri was with Pfizer where she was Senior Director of Global Implementation Lead. She has also worked with CorePharma, Endo Pharmaceuticals and Watson Pharmaceuticals. Sherri received her B.S. in Chemistry from Purdue University.
ACETO Corporation, incorporated in 1947, is a global leader in the marketing, sale and distribution of products for Human Health (finished dosage form generics and nutraceutical products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical
ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. ACETO's global operations, including a staff of 25 in China and 12 in India, are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.
This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO's reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO's Annual Report or Form 10-K for the fiscal year ended June 30, 2013 and other filings. Copies of these filings are available at www.sec.gov. ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
CONTACT: Investor Relations Contact:
The Ruth Group
Posted: September 2013